<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791032</url>
  </required_header>
  <id_info>
    <org_study_id>DOC-10246</org_study_id>
    <nct_id>NCT05791032</nct_id>
  </id_info>
  <brief_title>Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study</brief_title>
  <official_title>Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtaCor Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtaCor Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STEP ICD is a premarket, exploratory, early feasibility, interventional study designed to&#xD;
      evaluate early safety and performance of the Investigational Devices. The study is intended&#xD;
      to inform the final device design which will be further evaluated in traditional feasibility&#xD;
      and /or pivotal clinical investigations. Safety will be characterized through analysis of all&#xD;
      adverse events through 6 weeks post-implant and 30 days post-explant. VF sensing and&#xD;
      conversion of induced VF with the EV-ICD Lead over a 6 week implant period will be evaluated.&#xD;
      Pacing and subject sensation while pacing will also be evaluated over the study period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary safety endpoint is Incidence of Adverse Device Effects (ADEs). The primary&#xD;
      performance endpoint is Induced VF conversion success with ≥ 10J safety margin at 6 weeks.&#xD;
      Secondary endpoints include pacing capture threshold, pacing impedance, R-wave amplitudes and&#xD;
      sensation level while pacing.&#xD;
&#xD;
      Up to 30 eligible Subjects undergoing a pectoral transvenous ICD procedure (de novo or&#xD;
      replacement) will receive an EV-ICD Lead connected to a commercially available ICD in a left&#xD;
      mid-axillary pocket.&#xD;
&#xD;
      The EV-ICD System will be tested acutely to determine the lowest defibrillation energy.&#xD;
      Subjects will remain in the hospital overnight minimum, prior to discharge. Before discharge,&#xD;
      the EV-ICD will be programmed to monitor only (therapy OFF) to detect and store ventricular&#xD;
      arrhythmias over the follow-up period. Other non-therapy programming parameters will match&#xD;
      the transvenous ICD to the extent possible.&#xD;
&#xD;
      Follow-up visits are planned at 2 weeks (Day 11 to 17) and 6 weeks (Day 35 to 45). VF&#xD;
      conversion testing will occur again at the 6-week visit to determine if a ≥10J safety margin&#xD;
      exists.&#xD;
&#xD;
      The EV-ICD System will be removed on completion of the 6-week visit, leaving the transvenous&#xD;
      ICD system in place. A post-removal follow-up to assess any post-removal adverse events will&#xD;
      occur 25-35 days post-removal, prior to study exit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2023</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ADEs</measure>
    <time_frame>6 weeks post-implant</time_frame>
    <description>Incidence of Adverse Device Effects (ADEs) at 6 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced VF Conversion Success</measure>
    <time_frame>6 weeks post-implant</time_frame>
    <description>Induced VF conversion success rate at 6 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ventricular Arrythmia</condition>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>AtaCor EV-ICD Lead System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects implanted with the AtaCor EV-ICD Lead</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AtaCor EV-ICD Lead</intervention_name>
    <description>Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.</description>
    <arm_group_label>AtaCor EV-ICD Lead System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years old&#xD;
&#xD;
          2. Indicated for de novo or replacement ICD procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI ≥ 35 kg/m2&#xD;
&#xD;
          2. Subjects who require continual ventricular pacing&#xD;
&#xD;
          3. Presence or planned use of a subcutaneous ICD lead, subcutaneous coils/arrays,&#xD;
             epicardial patches or epicardial pace/sense leads within the study period&#xD;
&#xD;
          4. Planned MRI within the study period&#xD;
&#xD;
          5. Subjects on anticoagulation or antiplatelet therapy that cannot be temporarily&#xD;
             discontinued for the procedure&#xD;
&#xD;
          6. Circumstances that may prevent data collection or follow-up&#xD;
&#xD;
          7. Participation in any concurrent clinical study without prior written approval from the&#xD;
             Sponsor&#xD;
&#xD;
          8. Inability or unwillingness to provide informed consent to participate in the Study&#xD;
&#xD;
             Known prior history for any of the following:&#xD;
&#xD;
          9. NYHA IV functional class in past 90 days&#xD;
&#xD;
         10. Inotropic therapy in past 180 days&#xD;
&#xD;
         11. Structural abnormalities of the heart that may increase risk of the study procedure or&#xD;
             an obstructed/restricted pathway into the mediastinum&#xD;
&#xD;
         12. Uncontrolled paroxysmal, persistent or permanent atrial fibrillation&#xD;
&#xD;
         13. Median or partial sternotomy&#xD;
&#xD;
         14. Surgery with disruption of the lung, pericardium or connective tissue between the&#xD;
             sternum and pericardium&#xD;
&#xD;
         15. Significant anatomic derangement of or within the thorax (e.g., pectus excavatum,&#xD;
             significant scoliosis)&#xD;
&#xD;
         16. Thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical&#xD;
             treatments which may complicate the AtaCor EV-ICD Lead System implant procedure&#xD;
&#xD;
         17. Any conditions which may complicate the AtaCor EV-ICD Lead System implant procedure&#xD;
&#xD;
         18. Pericardial disease, pericarditis and mediastinitis&#xD;
&#xD;
         19. Medical treatments, surgeries or conditions that increase the potential for adhesions&#xD;
             in the thorax&#xD;
&#xD;
         20. FEV1 &lt; 1.0 Liter&#xD;
&#xD;
         21. Surgically corrected congenital heart disease (not including catheter-based&#xD;
             procedures)&#xD;
&#xD;
         22. Allergies to the device materials as listed in the Instructions for Use (IFU)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin C Burke, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>AtaCor Medical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Husby, MS, MPH</last_name>
    <phone>+1 949-392-8988</phone>
    <email>michael@atacor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Hase, BS, CCRA</last_name>
    <phone>+1 612-716-0654</phone>
    <email>sarah@atacor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <contact>
      <last_name>Santiago Gallo, MD</last_name>
      <phone>021202767</phone>
      <email>santigallo56@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adrian Ebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 29, 2023</last_update_submitted>
  <last_update_submitted_qc>March 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventricular Defibrillation</keyword>
  <keyword>Extravascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

